Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 21:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organon & Co....
May 08, 2025 21:00 ET | Source: Bragar Eagel & Squire

ORGANON ALERT: Bragar Eagel & Squire, P.C. is Investigating Organon & Co. on Behalf of Organon Stockholders and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organon & Co....
October 27, 2023 17:00 ET | Source: ObsEva SA

Organon Returns Ebopiprant to XOMA

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
July 27, 2021 01:00 ET | Source: ObsEva SA

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need Ad hoc...